GNLX

#3898
Genelux Corporation Common Stock
2.82 USD
+6.82%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
2.81
2.85
Rango anual
2.25
8.54
Cambio diario
+6.82%
Variación mensual
+6.82%
Variación en los últimos 6 meses
-48.73%
Cambio anual
+17.01%
Cierres anteriores
2.64
Abrir
2.82
Bid
Ask
Mínimo
2.81
High
2.85
Volumen
34
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
Informe de resultados Saldo Flujo de caja
Valor Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

Noticias